The Israeli Weekender
SEE OTHER BRANDS

Fresh news on arts and entertainment in Israel

The Israeli Weekender: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Israeli Weekender.

Press releases published on June 3, 2025

From Conflict to Compassion: Divided Homeland Inspires Author to Build Bridges Through Stories of Love

From Conflict to Compassion: Divided Homeland Inspires Author to Build Bridges Through Stories of Love

Michael Weiss feels called to inspire, uplift and connect readers through captivating stories of the human experience that transcend borders. NEW YORK, NY, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- Jerusalem-born author and entrepreneur Michael …

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash …

Nanox to Participate in Sidoti Small Cap Conference

Nanox to Participate in Sidoti Small Cap Conference

PETACH TIKVA, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will participate in the Sidoti Small Cap Conference to be held …

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for …

Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases

Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases

Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; Olmsted syndrome, severe keratoderma …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service